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Summary: Although two recent studies have failed to reveal lipoprotein(a) (LP(a)) serum concentrations
> 300 mg/1 to be an independent risk factor for early onset of atherosclerosis, Lp(a) serum concentrations are
frequently measured to evaluate the additional risk of coronary heart disease. We describe a time-resolved immu-
nofluorometric assay (TRIFMA) for quantifying Lp(a) levels in human serum using commercially available rea-
gents, which is rapid, robust and simple to perform. The two-site immunometric assay was based on microtitre
plates as solid phase coated with a polycloncal anti Lp(a) antibody. The liquid-phase antibody was labelled with
biotin and detected by europium labelled streptavidin in the DELFIA 1232 fluorometer. The measuring range was
2-1600 mg/1. The intra-assay imprecision was < 7% (CV), the inter-assay imprecision < 12% (CV). No interfer-
ence was detected with plasminogen concentrations up to 2.2 g/1. There was an acceptable correlation with a
commercially available enzyme immunoassay (r = 0.95) and with electroimmunodiffiision (r = 0.85) on 100 routine
serum samples measured. The assay appeared to detect different Lp(a) isoforms as dilution curves were parallel
for B/F, S2 and S4 isoforms.
Introduction
Numerous epidemiological and case-control studies
have revealed lipoprotein(a) (Lp(a)) serum concentra-
tions > 300 mg/1 to be an independent risk factor for
myocardial infarction, stroke and restenosis after coro-
nary artery bypass surgery (1—9). The results have been
confirmed by a prospective study (10). Ridker et al. and
Jauhiainen et al., however, could not show any correla-
tion between Lp(a) serum levels and atherosclerosis (11,
12). Nevertheless, Lp(a) serum concentrations are fre-
quently measured to estimate the additional risk of
atherosclerotic disease.
Lp(a)1) is a cholesterol ester-rich lipoprotein which re-
sembles LDL1) with the presence of apolipoprotein B^
*) Non-standard abbreviations:
Lp(a): h'poprotein(a); TRIFMA: time-resolved immunofluoromet-
ric assay; LDL: low density lipoprotein; IRMA: immunoradiomet-
ric assay; EIA: enzyme immunoassay; IEMA: immunoenzymomet-
ric assay.
100 to which the glycoprotein apolipoprotein(a) is cova-
lently bound. Apolipoprotein(a) contains three structural
regions, which are also present in plasminogen: variable
numbers of kringle 4, one kringle 5 and a protease do-
main (14). The number of kringle 4 repeats is a genetic
trait and determines the relative molecular mass ( )
polymorphism of apolipoprotein(a). In the Caucasian
population the frequency distribution of Lp(a) serum
concentration is markedly skewed with a shift toward
lower levels. Lp(a) serum concentrations are inversely
related to the size of apolipoprotein(a) isoforms and
range from less than 1 mg/1 to > 2000 mg/1 (9).
Several analytical methods have been described to quan-
tify Lp(a) levels in serum. Electroimmunodiffusion
(EID) was followed by radioimmunoassay (RIA) and
enzyme immunoassay (EIA) (16—20). Nephelometric
techniques have recently been introduced to automate
the Lp(a) determination (21, 22). These methods, how-
ever, are either difficult to perform in large series, time
consuming, or lack accuracy and precision at low and
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high concentrations of Lp(a). The use of radioimmuno-
assays is restricted to authorised laboratories.
We describe a non-radioisotopic Lp(a) assay, which of-
fers a wide measuring range, high sensitivity and low
intra- and inter-assay imprecision. The assay is rapid,
robust, simple to perform and suitable for routine use.
Materials and Methods
Samples
Serum was used as specimen throughout. The sera were measured
either directly after centrifugation or after being stored frozen at
-20 °C. Samples to define the reference range were obtained from
healthy blood donors. The plasma and serum samples for the com-
parison of measurement in plasma and serum were obtained from
healthy employees of the hospital.
many), and the DELFIA 1232 time-resolved fluorometer from
Pharmacia (Uppsala, Sweden).
Assay procedure
Microtitre plates were coated with 200 μΐ per well of sheep anti
Lp(a) antibody from Immuno (10 μΐ diluted in 20ml coating
buffer). Each plate was allowed to stand 'oVernight at 4 °C, then the
coating solution was aspirated, the plate washed once with washing
buffer, and 200 μΐ per well of assay buffer were added for storage.
Calibrators, controls and samples were diluted 1 :500 in assay
buffer. The calibrator containing 800 mg/1 Lp(a) was diluted
1 :250 to give a final concentration of 1600 mg/I. Twenty μΐ of
the diluted calibrators, controls and samples were pipetted into
each well, allowed to stand for 30 minutes at ambient temperature
(18-22 °C) followed by 200 μΐ assay buffer. After incubation for
one hour on the microtitre plate shaker with 200 min""1 at ambient
temperature, the plate was washed three times with washing buffer.
Reagents
All chemicals were analytical grade from Merck (Darmstadt, Ger-
many) or Sigma (Deisenhofen, Germany), if not stated otherwise.
We used double distilled water for all buffers and solutions.
Buffers
Assay buffer
Tris 0.05 mol/1, NaCl 0.15 mol/1, bovine serum albumin 5 g/1
(Sigma), bovine γ-globulin 0.5 g/1 (Sigma), diethylenetriaminepen-
taacetic acid (DTPA) 0.01 mol/1 (Sigma), NaN3 0.15 mmol/1,
Tween 20 0.2 ml/1 (Sigma), pH adjusted to 7.75.
Washing buffer
Tris 0.05 mol/1, NaCl 0.15 mol/1, Tween 20 l ml/l, pH 7.5. The
washing buffer was stored in a 40-fold concentrate and was stable
for half a year.
Coating buffer
Na2C03 0.05 mol/1, NaHCO3 0.05 mol/1, NaN3 0.15 mmol/1, pH
9.6.
Tab. 1 Influence of haemolysis on the Lp(a) concentrations mea-
sured with the Lp(a) TRIFMA. Ten serum samples were measured
directly and after mechanical treatment to produce haemolysis. On
the right the haemoglobin concentration in the sera after haemoly-
sis is given. The coefficient of correaltion for the Lp(a) concentra-
tions before and after haemolysis was r = 0.998.
Sample
no.
1
2
3
4
5
6
7
8
9
10
Lp(a) concentration
before
haemolysis
[mg/1]
60
420
620
260
9.9
440
590
16
245
58
after
haemolysis
[mg/I]
57
390
600
270
9.0
450
605
14
238
55
Haemoglobin
concentration
[g/1]
1.2
1.4
1.8
1.9
1.6
1.2
1.1
1.4
1.3
1.9
Enhancement solution
Citric acid 0.1 mol/1, tri-n-octyl-phosphine-oxide 0.01 mol/1, potas-
sium-phthalate 0.08 mol/1 (Sigma), thenoyltrifluoroacetone 0.01
mol/1 (Sigma), Triton X-100 2 ml/1 (Sigma).
Antibodies
The polyclonal Lp(a) antibodies were purchased from DAKO
(Hamburg, Germany), Code No. Q 023, Lot No. 062, and from
Immuno GmbH (Heidelberg, Germany) Art. No. 4845009, Lot No.
2421/360. The calibrator and the controls were from Immuno
GmbH, Art. No. 4395006 and Art No. 4395106, respectively.
Streptavidin was purchased from Biomol (Hamburg, Germany), the
europium labelling reagent was from Pharmacia (Uppsala, Swe-
den), Art. No. 1244-301. Microtitre plates were from Nunc
(Roskilde, Denmark), maxisorp F 96.
Apparatus
We used the Novopath Platewasher (Bio Rad, Munich, Germany),
the Heidolph microtitre plate shaker (Heidolph, Kelheim, Ger-
Tab. 2 Influence of triacylglycerol concentrations on the Lp(a)
concentrations measured with the Lp(a) TRIFMA. One sample
containing high level of Lp(a) (496 mg/1) and low level of triacyl-
glycerol (0.3 mmol/1) was mixed with another sample with low
Lp(a) concentration (47 mg/1) and high level of triacylglycerol
(15.7 mmol/1). No influence of triacylglycerol concentration on the
Lp(a) concentrations can be observed.
Fraction of
sample 1
1.00
0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0
Lp(a) concentration [mg/1]
sample 2
0
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
Measured
496
447
387
344
294
246 .
203
168
122
86
f7
Expected
496
451
406
361
316
272
227
182
137
92
47
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Two-hundred μΐ of DAKO anti Lp(a) antibody which had been
labelled with biotin as described previously (26) and diluted in
assay buffer to a final concentration of 1 mg/1 were incubated for
another hour (ambient temperature, 200 min~l). After washing
three times with washing buffer, 200 μΐ of the streptavidin euro-
pium conjugate in assay buffer were added to each well and incu-
bated for 30 minutes (ambient temperature, 200 min""1). Streptavi-
din was labelled as recommended by Pharmacia (Uppsala, Sweden)
using their europium labelling reagent and diluted to a final con-
centration of 0.025 mg/1. After a final washing step 200 μΐ en-
hancement solution were added to each well and then incubated
for 30 minutes (ambient temperature, 200 min"1). The plate was
measured in the DELFIA 1232 fluorometer. The calibration curve
was constructed using a modified spline function in the FIA-Calc
data reduction programme of the DELFIA 1232 system after a log/
log transformation of the data.
Tab. 3 Lp(a) levels in serum, heparin-, citrate- and EDTA-plasma
of 20 healthy hospital employees. The coefficients of correlation
for serum vs. citrate-plasma was r = 0.994, for serum vs. heparin-
ized plasma r = 0.998, for serum vs. EDTA-plasma r = 0.999,
respectively. (* Dilution effect of 1 : 10 must be taken into con-
sideration. These were the measured concentrations.)
Sample
no.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Lp(a) con-
centration
[mg/1]
Serum
54
143
22
71
100
33
25
19
12
360
130
22
9
59
1400
267
31
320
16
43
Lp(a) con-
centration
[mg/1]*
Citrate-
plasma
46
124
20
60
78
27
23
17
14
260
110
20
9
• 46
1560
. 257
27
230
13
33
Lp(a) con-
centration
[mg/1]
Heparin-
plasma
50
94
21
60
96
34
28
15
14
300
100
22
8
52
1200
296
29
290
13
38
Lp(a) con-
centration
[mg/1]
EDTA-
plasma
51
134
15
63
111
30
26
17
13
330
110
23
8
58
1240
285
33
290
19
34
Influence of haemolysis
To investigate the influence of haemolysis 10 blood samples were
divided into two aliquots each. One was immediately centrifuged
and the serum measured. The other was mechanically haemolysed
on a tube shaker. All samples were macroscopically haemolytic
after this procedure. The haemoglobin concentration after centrifu-
gation was between 1 and 2 g/1, as measured with the cyanmethae-
moglobin method (tab. 1).
Tab. 5 Stability of the coated Lp(a) microtitre plate stored for 3
months in assay buffer at 4 °C. Given are the calibrator concentra-
tions, the response and the concentrations of 3 control sera mea-
sured with plates prepared 1 week and 13 weeks before. (* Assay
date for both plates was 7. Feb. 1995.)
Calibrator
concentrati on
[mg/1]
2
10
50
200
800
1600
Response [counts/s]*
Plate coated
28. Oct. 1994
9071
30414
118040
365959
877622
1207095
Plate coated
6. Feb. 1995
9440
32016
122472
388782
968806
1209315
Concentration [mg/1]
Control 1
Control 2
Control 3
187
378
683
190
345
715
Tab. 4 Influence of storing conditions of Lp(a) measurement. Ten
serum samples stored at 4 °C and frozen at -20 °C for 21 days,
respectively. Another ten samples have been stored at 4 °C and at
-80 °C for the same time. The coefficients of correlation for Lp(a)
concentrations measured in samples stored at 4 °C vs. samples
stored at -20 °C was r = 0.996, for samples stored at 4 °C vs.
-80 °C r = 0.990, respectively.
Sam-
_i_pie
no.
1
2
3
4
5
6
7
8
9
10
Storing at
4°C
Lp(a)
[me/I}
32
110
451
40
>1600
14
747
984
24
387
-20 °C
Lp(a)
[rag/1]
26
130
426
33
>1600
14
671
836
21
358
Sam-
_1_pie
no.
Π
12
13
14
15
16
17
18
19
20
Storing at
4°C
Lp(a)
[mg/1]
379
197
490
34
116
83
40
155
35
257
-80°C
Lp(a)
[mg/1]
417
201
570
31
139
93
39
163
32
216
1000 -,
100-
10-r ' ' · M"i '— · ' ·
10 100 1000
Lp(a) concentration [mg/1]
Fig. 1 Calibration curve of the Lp(a) TRJFMA after log/log
transformation of the data.
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Tab. 6 Analytical recovery of the Lrj(a) TRIFMA. Eighteen serum samples were mixed 1 + 1
with' a serum containing 950 mg/1 Lp(a). The analytical recovery was calculated in percent.
Sample
no.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Serum Lp(a)
concentration
[mg/1]
403
201
100
7
640
995
7
108
543
241
10
77
52
8
298
389
204
19
Added concentration
[mg/1]
950
950
950
950
950
950
950
950
950
950
950
950
950
950
950
950
590
950
Expected value
[mg/1]
675
575
525
478
507
973
478
500
745
595
480
510
501
479
624
669
575
480
(by vol.)
Measured value
[mg/1]
675
 M598
501
429
503
1016
427
542
378
564
453
486
457
479
613
633
606
448
Recovery
[%]
100
102
95
87
99
104
89
108
99
95
94
95
91
100
98
95
106
93
Influence of lipaemia
To investigate the influence of hypertriacylglycerolaemia 2 sam-
ples were mixed with each other in steps of 10%. Sample 1 con-
tained 496 mgA Lp(a) and 0.3 mmol/1 triacylglycerols as deter-
mined in the routine laboratory. Sample 2 contained 47 mgA Lp(a)
and 15.7 mmol/1 triacylglycerols, respectively (tab. 2).
Interference of plasminogen
To assess the interference of plasminogen on the assay purified
plasminogen (Sigma) was diluted in assay buffer to give final con-
centrations of 0.1; 2.2; 22; 220 and 2200 mg/1, respectively and
measured in the assay. All concentrations were below the lowest
calibrator (0.06; 0.26; 1.1; 0.6 and 1.4 mg/1, respectively). Even
when measured without the obligate predilution corresponding to
a theoretical, original concentration of 1100 g/l(!) only 16 mg/1
were detected.
Measurement in serum and different kinds of plasma
To evaluate the effect of measuring Lp(a) in different derivatives
from blood, blood from 20 healthy employees of the hospital was
obtained as serum, heparinized plasma, EDTA-plasma and citrate-
plasma. Results are given in table 3.
Effect of storing conditions on Lp(a) levels
To assess the influence of storing conditions on the stability of
Lp(a) 10 serum samples were stored at 4 °C and -20 °C for 21
days. Another 10 samples were stored at 4 °C and -80 °C for the
same period (tab. 4). The effect of repeated freeze and thaw cycles
was not investigated, because the negative influence is well known.
Stability of coated microtitre plates
To evaluate the stability of the coated microtitre plates one plate
was stored for 13 weeks in assay buffer at 4 °C and compared with
a plate coated one week before (tab. 5).
Electroimmunodiffusion (EID)
Electroimmunodiffusion was performed in a 1 mm, anti Lp(a) anti-
serum containing agarose gel with a LKB-Multiphor II electropho-
resis unit (LKB-Pharmacia, Uppsala, Sweden) as described re-
cently (16, 23).
Enzyme immunoassay (EIA)
To quantify Lp(a) by EIA, the IMMUNOZYM Lp(a) EIA kit from
Immuno GmbH (Heidelberg, Germany) was used following the
manufacturers recommendations. This kit uses a monospecific,
polyclonal anti apolipoprotein(a) antibody on the solid-phase, and
a peroxidase labelled, monoclonal anti apolipoprotein(a) antibody
for detection (figs. 3 and 4).
Influence of apolipoprotein(a) isoforms on Lp(a)
measurement
To investigate, whether the TRIFMA measures irrespective of dif-
ferent isoforms of apolipoprotein(a), sera containing apolipopro-
tein(a) isoforms B/F, 82 and 84 (determined as described by
Laemmli (29)) were measured after serial dilution in assay buffer
(Fig. 5).
Measurement in triacylglycerol-rich fraction
To test Lp(a) measurement in triacylglycerol-rich fraction of se-
rum, sera were ultracentrifuged at 30000 min""1 for 18 hours and
Tab. 7 Intra-assay
TRIFMA.
and inter-assay imprecision of the Lp(a)
Mean con-
centration
[mg/i]
61 (n = 20)
372 (n = 20)
932 (n = 20)
Intra-assay
imprecision
CV [%]
2.81
4.10
6.77
Mean con-
centration
[mgA]
49 (n = 22)
193 (n = 22)
776 (n = 22)
Inter-assay
imprecision
CV [%]
11.5
6.64
9.83
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the supernatant and the remaining serum fraction measured sepa-
rately after serial dilution in assay buffer (fig. 6).
Statistical analyses
The correlation of Lp(a) levels between TRIFMA, BID and EIA,
was calculated using a non-parametric linear regression analysis as
described by Passing & Bablock (30). In the legends to the figures
2, 3 and 4 the coefficient of correlation (r), the equation formula
of the regression analysis (y = a + bx), the result of the Cusum
test for deviation from linearity (significant or not significant) and
the result of the test for contingency (p-values) are-given. To prove
the data in tables 1, 3 and 4 statistically, the coefficient of correla-
tion was calculated, instead of a statistical test, because of the low
number of data pairs.
Results
Assay characteristics
Figure 1 shows a typical calibration curve for the Lp(a)
TRIFMA. The potential lower detection limit was 0.39
mg/1, calculated as the response of the zero calibrator
(assay buffer) + 3 SD (n = 20). The measuring range
was 2-1600 mg/1. A high dose "hook" effect was not
detectable up to 5000 mg/1 (response for the 1600 mg/1
calibrator: 1 014527 counts/s, response for 5000 mg/1:
1 689 754 counts/s). Analytical recovery ranged from 87
to 108% (tab. 6). The intra-assay imprecision was < 7%
(CV, n = 20), the inter-assay imprecision was < 12%
(CV, n = 22) (tab. 7).
To calculate the reference range of Lp(a) in this assay,
specimens from 88 healthy blood donors were mea-
sured. There is a wide range of Lp(a) levels in healthy
individuals which does not follow a Gaussian distribu-
tion, as previously described (13). Thus, we calculated
the median, the 75th, 90th and 95th percentile instead of
the arithmetic mean. The median of the 88 samples was
99 mg/1, which corresponds well with the literature (24),
the 75th percentile was 362 mg/1, the 90th 569 mg/1 and
the 95th 670 mg/1 Lp(a), respectively. There was no in-
terference with plasminogen detectable up to a plasmin-
ogen concentration of 2.2 g/1 (10 fold above the upper
limit of the reference range) and no interference with
lipaemic or haemolytic samples, either (tabs. 1 and 2).
The Lp(a) TRIFMA was compared with the EIA from
Immuno and the electroimmunodiffiision technique. The
results of the TRIFMA correlated highly with the EIA
(r = 0.95; y = 1.47 χ + 7.66, Cusum test on deviation
from linearity: not significant, test for contingency:
ρ = 0.003, η = 100; fig. 2). Differences were seen in
low (< 40 mg/1) and high concentrations (> 450 mg/1).
The correlation between the results of the TRIFMA and
the electroimmunodiffiision assay (EID) was not as good
as the latter, probably because of the better linearity of
the TRIFMA over a wide measuring range (r = 0.85;
y = 1.38 χ — 69.7; Cusum test on deviation from linear-
ity: not significant, test for contingency: p = 0.308,
n = 100; fig. 3). This conjecture is supported by the bet-
ter correlation between EIA and EID (r = 0.92;
y = 0.98 χ - 61.6; Cusum test on deviation from linear-
ity: not significant, test for contingency: p = 0.065,
n = 100; fig. 4).
Figure 5 shows the influence of different apolipopro-
tein(a) isoforms on the Lp(a) measurement with the
Lp(a) TRIFMA. The distribution of Lp(a) between the
1500
1000
500
1500
500 1000
Lp(a)(EIA)[mg/l]
1500
Fig. 2 Plot of the regression analysis of Lp(a) serum levels as
determined by enzyme immunoassay (EIA = x) and time-resolved
immunofluorometric assay (TRIFMA = y) (r = 0.95; y = 1.47 χ
+ 766; as described by Passing & Bablok, Cusum test on deviation
from linearity: not significant, test for contingency: ρ = 0.003,
η =100).
htOOO
f 500
500 1000
Lp(a) (EID) [mg/1]
1500
Fig. 3 Plot of the regression analysis of Lp(a) serum levels [mg/1]
as determined by electroimmunodiffusion (EID = χ) and time-re-
solved immunofluorometric assay (TRJFMA = y) (r = 0.85;
y = 1.28 χ ~ 69.7; as described by Passing & Babhk, Cusum test
on deviation from linearity: not significant, test for contingency:
ρ = 0.308, η = 100).
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Fig. 4 Plot of the regression analysis of Lp(a) serum levels as
measured by electroimmunodirrusion (EID = χ) and enzyme
immunoassay (EIA = y) (r = 0.92; y = 0.98 χ -61.6; as de-
scribed by Passing & Bablok, Cusum test on deviation from
linearity: not significant, test for contingency: ρ = 0.065,
η = 100).
10000 r
1000
100
10
8 16
Dilution factor
32 64 128
Fig. 5 Influence of different apolipoprotein(a) isoforms on the
Lp(a) measurement with the Lp(a) TRIFMA. Three sera were seri-
ally diluted in assay buffer and Lp(a) concentrations were mea-
sured. Serum 1 (o) had a Lp(a) concentration of 2000 mg/1, the
apolipoprotein(a) isoform was determined as B/F, serum 2 (Π) had
a Lp(a) concentration of 440 mg/1, apolipoprotein(a) isoform was
S?, serum 3 (A) contained 50 mg/1 Lp(a) and apolipoprotein(a)
isoform 84.
supernatant and the remaining fluid after ultracentrifuga-
tion is shown in figure 6.
Discussion
Numerous investigations have revealed Lp(a) to be a
genetically determined, independent risk factor for coro-
nary heart disease, cerebrovascular disease and periph-
eral arterial occlusion (1 -9) although two studies, how-
ever, have failed to confirm these results (11, 12). Lp(a)
serum levels are quantified routinely with different ana-
lytical methods.
Electroimmunodiflusion (EID) is often referred to as the
"standard" method to measure Lp(a) (15, 16) and has
been used to investigate Lp(a) in many studies. It is a
simple and robust method, which is on the one hand not
sensitive enough to detect low levels of Lp(a) and on
the other hand not suitable for measuring large numbers
of samples. Only 25 samples can be applied per gel and
it takes two days until results are available. The nephelo-
metric and turbidimetric assays can be completely auto-
mated using modern nephelometers but difficulties can
arise with lipaemic or haemolytic sera (13). Further-
more, Lp(a) with its inverse relation between particle
size and serum concentration is not the most suitable
analyte for these techniques. These problems do not oc-
cur in sandwich immunoassays using either enzyme
linked or radiolabelled antibodies for detection. Immu-
noradiometric assays (IRMA) and immunoenzymomet-
ric assays (IEMA) show excellent sensitivity and speci-
fity (16-20). They are capable of assaying large num-
bers of samples. The use of radiolabelled substances,
however, limits the suitability of such methods for rou-
tine laboratory application.
10000 p
4 s
Dilution factor
32
Fig. 6 Four sera were ultracentrifuged at 30000 min"1 for 18
hours. The supernatant containing the triacylglycerol-rich fraction
was separated and the supernatant and the remaining serum were
separately measured in the Lp(a) TRIFMA after serial dilution in
assay buffer. Serum I contained 26 mg/1 Lp(a) in the supernatant
(+) and 4 mg/1 in the remaining fluid (+), serum Π contained 848
mg/1 (A) and 384 mg/1 (#), serum III 1110 mg/1 (·) and 1307 mg/1
(D) and serum IV 216 mg/l (·) and 50,mg/1 (O), respectively.
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Our data show, that Lp(a) has been stable for at least 3
weeks at 4 °C, -20 °C and -80 °C (tab. 4). The calibra-
tors and controls have been stored for 2 years at —80 °C
without any loss of immunoreactivity. This is in agree-
ment with the experience of other investigators ((23) and
Wood, personal communication). Therefore, we cannot
support the experience of Craig et al. (27) as far as two-
site immunometric assays are concerned. The effect of
freezing and thawing has been described previously
(28).
The different immunoreactivity of the Lp(a) isoforms
remains a problem in Lp(a) quantification. In our studies
dilution experiments with samples containing different
apolipoprotein(a) isoforms showed linear dilution curves
irrespective of the apolipoprotein(a) isoform, when mea-
sured with our method. Thus, it can be concluded, that
the TRIFMA measures Lp(a) independently of apolipo-
protein(a) isoforms. This may be explained by the use
of two polyclonal antibodies in this assay. Furthermore,
dilution experiments after separating the triacylglycerol-
rich fraction of serum and measuring both fractions
separately showed linear and parallel dilution curves in
different Lp(a) concentration ranges irrespective of the
serum fraction (fig. 6). These data suggest, that the
TRIFMA can also measure free apolipoprotein(a). This
can, however not be proved exactly due to lack in avail-
ability of free apolipoprotein(a), although both antibod-
ies are directed against apolipoprotein(a) and not Lp(a).
The assay described here offers some advantages over
other methods for Lp(a) quantification. In contrast to a
similar assay described recently (23), we used the biotin
streptavidin system with europium labelled streptavidin
for the detection of the second antibody. Jürgens et al.
(23) labelled their polyclonal anti apolipoprotein B or
anti Lp(a) antibodies directly with europium. However,
this is expensive because of the high price of the euro-
pium labelling reagent. Biotinylation of the antibody and
europium labelling of streptavidin reduces the cost, be-
cause biotin is cheap and every labelled streptavidin
molecule can, at least in theory, react specifically with
biotin.
Our method was not affected by triacylglycerols (tab. 2)
or haemolysis (tab. 1). The interference of plasminogen
was neglegible (s. results). The assay offers a wide
measuring range and a lower detection limit, which is
satisfactory for both clinical and research purposes. The
accuracy and the easy and rapid performance make the
method well suited for routine use.
Even if there is still some discussion about the clinical
validity of Lp(a), this analyte is frequently measured.
No "gold standard" exists for quantifying Lp(a). In this
paper we describe a method, which exclusively makes
use of commercially available reagents and which in-
cludes the biotin steptavidin system. Therefore this as-
say can be performed in many laboratories, e. g. with use
of streptavidin-enzyme or -isoluminol labelling, reagents
which are both commercially available.
We compared the TRIFMA (25) with an EIA and with
the EID-method and found a good correlation with both
methods (figs. 2 and 3). Differences, however, were seen
at low and high concentrations of Lp(a). This can be
explained by the superior ability of the TRIFMA to de-
tect low and high Lp(a) levels. The Lp(a) assay de-
scribed here has been successfully used as routine
method for quantifying Lp(a) in our laboratory for more
than 11/2 years.
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